AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
Cipla Health reinforces importance of Self-Care This Season Through Its Range of Wellness Products
With a rise in COVID cases and seasonal flu, Cipla Health's trusted…
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)…
HUTCHMED to Announce 2025 Half-Year Financial Results
July 03, 2025 04:30 ET | Source: HUTCHMED (China) Limited HONG KONG…
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to…
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England, July 3, 2025 /PRNewswire/ -- MatOrtho® is proud to announce…
Global Excel Acquires First Assistance to Strengthen Assistance Services and Expand in the Asia-Pacific Market
SHERBROOKE QC, July 2, 2025 /PRNewswire/ -- Global Excel Management Inc. (Global Excel)…
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward…
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 02, 2025 01:00 ET | Source: BioVersys Ad hoc announcement pursuant…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1…